Marshall Posner, MD, on the Promise of Personalized mRNA Vaccines in Solid Malignancies

Marshall Posner, MD, detailed the potential for personalized mRNA vaccines to treat patients with various different tumors and what information is still needed.

Marshall Posner, MD, professor of medicine, director of head and neck medical oncology, and associate director of the Center for Personalized Cancer Therapeutics, Icahn School of Medicine at Mount Sinai, spoke with CancerNetworkÒ at the 2021 European Society of Medical Oncology Congress about exciting future innovations in oncology, including the prospect of personalized mRNA vaccines for various solid tumors. Although promising data have read out on this modality, Posner addresses hurdles that need to be overcome before the treatment can roll out.


There were some very interesting abstracts on precision vaccines, [which are] based on individual patient tumor targets. There are some very interesting data coming out on the ability to create these [vaccines]. I think the ability to create a vaccine that's mRNA based is really going to accelerate the ability to make individualized vaccines for various tumors. Once again, the problem will be the same. What else do you need besides the vaccine and the checkpoint blockade inhibitor, which is what people are generally using, to produce a robust immune response?

Related Videos
Although opioid use guidelines from the Centers for Disease Control exclude patients with cancer, drug screenings are required that could further contribute to racial disparities.
An expert from Dana-Farber Cancer Institute says that policymakers and insurers should take a hard look at policies that restrict opioid use in patients with cancer who are at end of life, especially for underserved communities.
After assessing racial disparities in opioid access in older patients with cancer, an expert from Dana-Farber Cancer Institute speaks to the need for examining younger populations and those with different insurance types.
An expert from Dana-Farber Cancer Institute states that although giving opioids for minor procedures could lead to substance abuse issues, use of the drugs to manage end of life cancer pain should not be up for debate.
An expert from Dana-Farber Cancer Institute discusses data from a study investigating racial inequities in opioid access among patients of cancer near the end of life.
An expert from Dana-Farber Cancer Institute describes several key strategies for mitigating racial disparities in opioid access among patients with cancer near end of life.
PARP inhibitors like rucaparib should be considered to treat all kinds of patients, including those who have deleterious mutations and HIV, according to Amit Oza, MD, MBBS, FRCPC.
PARP inhibitors such as rucaparib appear to garner the most benefit in the early maintenance setting in patients with ovarian cancer who have less advanced disease and less heterogeneity, according to Amit Oza, MD, MBBS, FRCPC.
Abiraterone and olaparib continued to demonstrate a positive trend in overall survival (OS) in patients with metastatic castration-resistant prostate cancer, according to Fred Saad, MD, FRCS, though he stated that longer follow-up is needed to confirm the benefit.
Related Content